NASH Core Curriculum: Risk Factors and Prognostic Indicators

Learn about who is at risk and should be evaluated for progression to advanced fibrosis in NASH.
Manal F. Abdelmalek, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 5.50 MB
Released: March 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Related Content

Learn about renoprotection in diabetic kidney disease, CKD and CV outcomes; focus on emerging MR antagonists, from Clinical Care Options (CCO)

George L. Bakris, MD Vivian A. Fonseca, MD, FRCP Susanne Nicholas, MD, MPH, PhD Released: June 22, 2021

CCO Slides on T2D: Latest expert advice on SGLT2 inhibitors to prevent and manage heart failure, including HFrEF and HFpEF, in type 2 diabetes.

Jennifer B. Green, MD Mikhail N. Kosiborod, MD Released: June 7, 2021

Unlocked slides from Giada Sebastiani, MD and CCO: Role of diet, exercise, and current treatments for NASH

Giada Sebastiani, MD Released: June 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue